Daphne Quimi - 05 Jun 2025 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Director
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol: AMLX
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2025, 16:07:56 UTC
Previous filing: 16 Sep 2024
Next filing: 16 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Quimi Daphne	Director	C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE	/s/ Joshua B. Cohen, as Attorney in Fact	09 Jun 2025	0001543031

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (right to buy)	Award	$0	+25,000		$0.000000	25,000	05 Jun 2025	Common Stock	25,000	$5.05	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.